BKT140 reduces the growth of acute myeloid leukemia and multiple myeloma [97], disrupts the CXCL12-mediated adhesion of tumor cells to stromal cells to improve the efficacy of radiotherapy and chemotherapy in lung cancer [98], and plays a prominent role in the treatment of lymphoma. Here, CXCL12 is linked to plasma cell myeloma.